Buy Enap pills 5 mg, 20 pcs
  • Buy Enap pills 5 mg, 20 pcs


Krka dd Novo mesto AO
1556 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Enap is an antihypertensive drug whose mechanism of action is associated with the inhibition of the activity of the angiotensin-converting enzyme, leading to a decrease in the formation of angiotensin-II.
Enalapril is a “prodrug”: as a result of its hydrolysis, enalaprilat is formed, which inhibits ACE. The mechanism of its action is associated with a decrease in the formation of angiotensin I from angiotensin II, the reduction of which leads to a direct decrease in the release of aldosterone. At the same time, the total peripheral vascular resistance, systolic and diastolic blood pressure (BP), post- and preload on the myocardium decrease.
Expands the arteries to a greater extent than the veins, while a reflex increase in heart rate is not observed.
The hypotensive effect is more pronounced with a high level of plasma renin than with its normal or reduced level. A decrease in blood pressure (BP) within the therapeutic limits does not affect cerebral circulation, the blood flow in the brain vessels is maintained at a sufficient level and against the background of reduced blood pressure. Enhances coronary and renal blood flow.
With prolonged use, the left ventricular hypertrophy of the myocardium and myocytes of the walls of resistive arteries is reduced, it prevents the progression of heart failure and slows down the development of left ventricular dilatation. Improves blood supply to ischemic myocardium. Reduces platelet aggregation.
It has some diuretic effect.
The onset of the hypotensive effect when taken orally - 1 hour, reaches a maximum after 4-6 hours and lasts up to 24 hours. In some patients, therapy for several weeks is necessary to achieve an optimal level of blood pressure. In heart failure, a noticeable clinical effect is observed with prolonged use - 6 months or more.


- Arterial hypertension.
- Chronic heart failure (as part of combination therapy).
- Asymptomatic dysfunction of the left ventricle (as part of combination therapy).


1 tablet contains: enalapril maleate 5 mg.
Excipients: lactose monohydrate, hydroxypropylcellulose, corn starch, sodium bicarbonate, talc, magnesium stearate.

Enalapril is marketed under different brands and generic names, and comes in different dosage forms:

Brand nameManufacturerCountryDosage form
Enap Krka dd Novo mesto AO Slovenia pills
Enam Dr. Reddy`s India pills
Obolensky OP Russia pills
Enalapril PFK Obnovlenie Russia pills
Enalapril Izvarino Pharma Russia pills
Enap 2.5 and 5 mg 60 pcs. Krka dd Novo mesto AO Slovenia pills
Enalapril-FPO Obolensky OP Russia pills
Enalapril Sandoz Switzerland pills
Berlipril Berlin-Chemie/Menarini Germany pills
Ednite Gedeon Richter Hungary pills
Renitec Merck Sharp & Dohme USA pills
Enalapril Hemofarm Serbia pills

No customer reviews for the moment.

Write your review

Write your review


Dosage and Administration

pills should be taken orally with a small amount of liquid. pills can be taken before, during or after meals. You should get used to taking the drug regularly and at the same time.
If the patient misses taking the drug, it should be taken as soon as possible, but not if there are several hours left before taking the next dose. In this case, you should take only the next dose according to the scheme and not take the missed dose. Doses should never be doubled.
Enapom treatment requires regular medical examinations, especially at the beginning of treatment and / or when determining the most appropriate dose of the drug. The frequency of medical examinations is determined by the attending physician. The dose of the drug is always adjusted depending on the condition of the patient.
Treatment of hypertension: The recommended starting dose is 5 mg once daily. After taking the initial dose, patients should be under medical supervision for 2 hours and an additional 1 hour until blood pressure stabilizes. Dose adjustment depends on achieving a therapeutic effect (lowering blood pressure) and, in the absence of a clinical effect, increases in 1–2 weeks by 5 mg. The maintenance dose is usually from 10 to 20 mg, if necessary, and with sufficiently good tolerance, the dose can be increased to 40 mg per day. The maximum daily dose is 40 mg. At higher doses, it is advisable to divide into 2 doses.
Treatment of hypertension in special clinical situations: The initial dose for patients who have not been able to interrupt diuretic intake before starting Enap treatment is 2.5 mg as a single dose. Patients with hyponatremia (the concentration of sodium ions in the serum is less than 130 mmol / l) or the concentration of creatinine in the serum more than 0.14 mmol / l, the initial dose is 2.5 mg 1 time per day. Older patients are more likely to have a more pronounced hypotensive effect and lengthening the time of action of the drug, which is associated with a decrease in the rate of enalapril elimination, therefore the recommended initial dose to the elderly is 1.25 mg.
Treatment of congestive heart failure:The recommended starting dose is 2.5 mg once daily. The dose of Enap should be increased gradually until the maximum clinical effect is achieved, usually in 2 to 4 weeks. The usual maintenance dose ranges from 2.5 mg to 10 mg as a single dose; the maximum maintenance dose is 20 mg twice a day.
Treatment of asymptomatic left ventricular dysfunction:The recommended starting dose is 2.5 mg twice daily; some dose adjustment depends on the tolerance of the drug to patients. Usually the maintenance dose is 10 mg twice a day.
Treatment of hypertension in kidney disease:dose of Enap is determined depending on the renal function and / or indicators of creatinine clearance. For patients with creatinine clearance of more than 0.5 ml / sec (30 ml / min), the initial dose is 5 mg per day. For patients with creatinine clearance less than 0.5 ml / sec (30 ml / min), the initial dose is 2.5 mg per day and gradually increases until a clinical effect is achieved.
Treatment of patients on hemodialysis: for patients on the day of hemodialysis, 2.5 mg; on other days, the doctor adjusts the dose in accordance with blood pressure indicators.
Treatment by Enap is long, usually throughout life, unless circumstances arise that require its cancellation.

Adverse reactions

Classification of the incidence of side effects (WHO): very often {> 1/10), often (> 1/100 and <1/10), infrequently (> 1/1000 and <1/100), rarely (> 1/10 000 and <1/1000), very rarely (<1/10 000), including individual messages.
On the part of the hematopoietic system: rarely - neutropenia, decrease in hemoglobin and hematocrit, thrombocytopenia, agranulocytosis, inhibition of bone marrow hematopoiesis, pancytopenia, lymphadenopathy, autoimmune diseases; very rarely - anemia (including aplastic and hemolytic).
On the part of metabolism: infrequently - exacerbation of the course of gout, hypoglycemia.
On the part of the nervous system: very often - dizziness, weakness; often - headache, asthenia, depression; infrequently - insomnia, drowsiness, paresthesia, irritability; rarely, unusual dreams, sleep disturbances; very rarely - confusion, insomnia.
From the senses: often - changes in taste; Infrequently - tinnitus, blurred vision.
Since the cardiovascular system: often - marked reduction in blood pressure, orthostatic hypotension, syncope, chest pain, cardiac arrhythmias (atrial brady- or tachycardia, atrial fibrillation), tachycardia, angina pectoris; infrequently - a feeling of heartbeat, myocardial infarction or stroke (due to a pronounced decrease in blood pressure); rarely - thromboembolism branches of the pulmonary artery, Raynaud's syndrome.
On the part of the respiratory system: very often - cough; often - shortness of breath; infrequently - rhinorrhea, sore throat and hoarseness, bronchospasm; rarely, pulmonary infiltrates, rhinitis, allergic alveolitis / eosinophilic pneumonia.
On the part of the digestive system: very often - nausea; often - diarrhea, abdominal pain, flatulence; infrequently - ileitis, intestinal obstruction, pancreatitis, vomiting, constipation, anorexia, dryness of the oral mucosa, peptic ulcer; rarely, liver dysfunction and biliary excretion, hepatitis (hepatocellular or cholestatic), cholestatic jaundice, fulminant necrosis of the liver, stomatitis / aphthous ulcers, glossitis; very rarely - intestinal angioedema.
For the skin: often - skin rash; infrequently - exudative erythema multiforme, exfoliative dermatitis, toxic epidermal necrolysis, pemphigus, erythroderma, profuse sweating, pruritus, urticaria, alopecia, photosensitization.
From the urinary system: infrequently - impaired renal function, acute renal failure; rarely - oliguria.
On the part of the reproductive system: infrequently - decrease in potency, decrease in libido; rarely - gynecomastia.
From the musculoskeletal system: often - muscle spasms; infrequently - arthralgia.
From the laboratory parameters: often - hyperkalemia, increased serum creatinine concentration; infrequently - hyperglycemia, hyperuricemia, hypokalemia, hyponagriemia, increased serum urea concentration; rarely, increased liver transaminase activity and bilirubin concentration.
Allergic reactions: Infrequently - Stevens-Johnson syndrome; rarely - angioedema of the face, lips, tongue, pharynx, larynx, extremities.
Others: a symptom complex has been described, which may include fever, myalgia and arthralgia, serositis, vasculitis, increased erythrocyte sedimentation rate, leukocytosis and eosinophilia, skin rash, a positive test for antinuclear antibodies. Also, a symptom complex has been described, which includes facial flushing, nausea, vomiting, and arterial hypotension and may develop with simultaneous use of ACE inhibitors and gold preparations (sodium aurothiomalate) IV.


- Hypersensitivity to enalapril or other components of the drug.
- Hypersensitivity to other ACE inhibitors.
- Angioedema in the history of, including the use of ACE inhibitors (allergic reaction with a sharp swelling of the lips, face, neck, and possibly hands and feet, accompanied by suffocation and hoarseness).
- Porphyria.
- Pregnancy.
- Lactation (breastfeeding).
- Patients who have ever had angioedema.
- Age up to 18 years (efficacy and safety have not been established).
- Bilateral renal artery stenosis.
- Stenosis of the artery of a single kidney.
- Primary hyper aldosteronism.
- Hyperkalemia.
- Condition after kidney transplantation.
- Aortic stenosis.
- Mitral stenosis (with impaired hemodynamics).
- Idiopathic hypertrophic subaortic stenosis.
- Systemic diseases of the connective tissue.
- Coronary heart disease.
- Inhibition of bone marrow hematopoiesis.
- Cerebrovascular diseases.
- Diabetes.
- Renal failure (proteinuria - more than 1 g / day).
- Liver failure.
- In patients on a salt-restricted diet.
- In patients on hemodialysis.
- Simultaneous administration with immunosuppressants and saluretics.
- In the elderly (over 65).

Drug interactions

The patient should refrain from taking alcoholic beverages, since ethanol enhances the reduction of blood pressure (BP) with enalapril.
The simultaneous use of enalapril and diuretics or other antihypertensive drugs increases the effectiveness of these drugs.
Interaction with drugs used to treat heart failure (cardiac glycosides) has no clinical significance.
Before surgery, the physician should be informed that the patient is taking enalapril because there is a risk of arterial hypotension during general anesthesia.
The simultaneous use of enalapril and nonsteroidal anti-inflammatory drugs (NSAIDs) or acetylsalicylic acid (aspirin), as well as estrogen can reduce the effectiveness of enalapril and increase the risk of renal dysfunction.
The simultaneous use of certain diuretics (spironolactone, amiloride, or triamterene) and / or the additional prescription of pills containing potassium may cause an increase in the level of serum potassium (hyperkalemia).
Drugs that cause bone marrow depression increase the risk of developing neutropenia and / or agranulocytosis.
Immunosuppressants, allopurinol, cytostatics increase hematotoxicity.
Enalapril weakens the effect of products containing theophylline.
The simultaneous use of lithium preparations may enhance the side effects of lithium.
At the same time taking the drug Enap with cimetidine increases the half-life (T 1/2) of Enap. If the patient is already taking the above drugs or is advised to take any of them, he should inform the doctor that he is taking Enap.

Pregnancy and Lactation

During pregnancy and lactation can not prescribe the drug. If pregnancy occurs during the period of treatment by Enap, you should inform your doctor as soon as possible. He will prescribe another antihypertensive treatment.

Special instructions

Hypotension (a sharp decrease in blood pressure) can be observed (even several hours after taking the first dose) in patients with severe heart failure or severe impaired renal function, as well as in patients with impaired water and electrolyte balance due to diuretic therapy, salt-free diets, diarrhea, vomiting or being on hemodialysis. A marked reduction in blood pressure (BP) is usually manifested in the form of nausea, an increase in heart rate (HR) and fainting.
In the event of arterial hypotension, the patient needs to take a horizontal position with a low head and call a doctor.
Hypotension and its serious consequences are rare and have a transient nature. Transient hypotension is not a contraindication to further treatment with the drug. As soon as the blood pressure stabilizes, the patient normally tolerates receiving subsequent doses of the drug. Hypotension can be avoided by interrupting diuretic treatment and avoiding a salt-free diet before starting treatment with Enap, if possible.
If there is a recurrence of hypotension, accompanied by symptoms such as nausea, increased heart rate (HR) and fainting, you should consult a doctor.
Renal function should be monitored before and during treatment with Enap.During treatment with Enap, an increase in serum potassium is possible, especially in patients with chronic renal failure, diabetes mellitus, with simultaneous administration of potassium-saving diuretics (such as spironolactone, amiloride and triamterene) or pills containing potassium. Therefore, while taking Enap and these drugs, you must strictly follow the instructions of the doctor. If the patient feels muscle weakness or irregular heartbeats during the period of such treatment, you should immediately inform your doctor.
Allergic reactions can develop due to the use of some types of filtering membranes used in hemodialysis or other types of blood filtration (apheresis). If the doctor plans such treatment, he should be warned about the simultaneous treatment of Enap.
During the period of allergy treatment (desensitization) to aspen or bee venom, hypersensitivity reactions may occur. If the doctor plans such treatment, he should be warned about the simultaneous treatment of Enap.
The efficacy and safety of the drug in the treatment of children has not been established, so it should not be prescribed to children.
Influence on ability to drive motor transport and control mechanisms: in some patients, the drug can cause severe arterial hypotension and dizziness, especially at the beginning of treatment, thus having an indirect and transient effect on the ability to drive vehicles and machinery.


If the patient has taken too many pills at one time, you should immediately call a doctor.
Symptoms: excessive reduction of blood pressure (BP) until the development of collapse, myocardial infarction, acute cerebrovascular accident or thromboembolic complications, convulsions, stupor.
Treatment: the patient is transferred to a horizontal position with a low head. In mild cases, gastric lavage and ingestion of a saline solution are shown, in more serious cases, measures aimed at stabilizing arterial pressure (BP), intravenous saline, plasma substitutes, if necessary, intravenous angiotensin II, hemodialysis (speed removal of enalaprilat - 62 ml / min).

  • Brand name: Enap
  • Active ingredient: Enalapril
  • Dosage form: Pills.
  • Manufacturer: Krka dd Novo mesto AO
  • Country of Origin: Slovenia

Studies and clinical trials of Enalapril (Click to expand)

  1. Preparation and characterization of enalapril maleate–loaded nanoparticles using amphiphilic diblock copolymers
  2. Hypertensive crisis in systemic sclerosis: treatment with the new oral angiotensin converting enzyme inhibitor mk 421 (enalapril) in captopril-intolerant patients
  3. Pharmacokinetic assessment of an oral enalapril suspension for use in children
  4. Pharmacokinetics of repeated single oral doses of enalapril maleate (mk-421) in normal volunteers
  5. Pharmacokinetic comparison of a combination tablet of enalapril and hydrochlorothiazide with enalapril and hydrochlorothiazide tablets administered together and separately
  6. Bioequivalence evaluation of two brands of enalapril 20mg tablets (narapril and renitec) in healthy human volunteers
  7. Determination of enalapril maleate and atenolol in their pharmaceutical products and in biological fluids by flow-injection chemiluminescence
  8. Determination of enalapril and its active metabolite enalaprilat in plasma and urine by gas chromatography/mass spectrometry
  9. The effects of enalapril maleate and cold stress exposure on tyrosine hydroxylase activity in some rat tissues
  10. Enalapril maleate affects 2-oxoglutarate metabolism in mitochondria from the rat kidney cortex
  11. Comparative hypotensive activity of REV 6207 and enalapril in the conscious furosemide-treated monkey
  12. Angiotensin-converting enzyme inhibition by enalapril: A novel approach to reduce ischemia/reperfusion damage after experimental liver transplantation
  13. The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein
  14. Potential effect of enalapril on clomipramine metabolism
  15. Antifibrotic effect of captopril and enalapril on paraquat-induced lung fibrosis in rats
  16. Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats
  17. Synthesis of 3h-labelled enalapril maleate
  18. Comparison of APPI, APCI and ESI for the LC-MS/MS analysis of bezafibrate, cyclophosphamide, enalapril, methotrexate and orlistat in municipal wastewater
  19. Direct monitoring of drug degradation by easy ambient sonic-spray ionization mass spectrometry: the case of enalapril
  20. Structure determination of enalapril maleate form II from high-resolution X-ray powder diffraction data
  21. Influence of food on the bioavailability of enalapril
  22. Simultaneous determination of enalapril, felodipine and their degradation products in the dosage formulation by reversed-phase high-performance liquid chromatography using a Spherisorb C8 column
  23. Conformational analysis of enalapril (MK-421) in solution by 1H and 13C NMR
  24. Use of microcalorimetry in determination of stability of enalapril maleate and enalapril maleate tablet formulations

Customers who bought this product also bought:

8 other products in the same category: